James D. Griffin

Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis

Ross L. Levine, Martha Wadleigh, Jan Cools et al. · Cancer Cell · 2005 · 3K citations · Full text

Medicine, Genetics, Hematology +14

A Tyrosine Kinase Created by Fusion of the <i>PDGFRA</i> and <i>FIP1L1</i> Genes as a Therapeutic Target of Imatinib in Idiopathic Hypereosinophilic Syndrome

Jan Cools, Daniel J. DeAngelo, Jason Gotlib et al. · New England Journal of Medicine · 2003 · 1.7K citations · Full text

Life Sciences, Genetics, Hematology +15

Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl

Ellen Weisberg, Paul W. Manley, Werner Breitenstein et al. · Cancer Cell · 2005 · 1.5K citations · Full text

Pharmacy, Medicinal Chemistry, Molecular Biology +6

Nilotinib in Imatinib-Resistant CML and Philadelphia Chromosome–Positive ALL

Hagop M. Kantarjian, Francis J. Giles, Lydia Wunderle et al. · New England Journal of Medicine · 2006 · 1.3K citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13

The product of the retinoblastoma susceptibility gene has properties of a cell cycle regulatory element

James A. DeCaprio, John W. Ludlow, Dennis C. Lynch et al. · Cell · 1989 · 928 citations

Life Sciences, Genetics, Molecular Genetics +11